Alta Advisers Ltd Makes New $1.10 Million Investment in Johnson & Johnson (NYSE:JNJ)

Alta Advisers Ltd bought a new position in shares of Johnson & Johnson (NYSE:JNJGet Rating) in the third quarter, HoldingsChannel reports. The firm bought 6,700 shares of the company’s stock, valued at approximately $1,095,000. Johnson & Johnson accounts for 0.7% of Alta Advisers Ltd’s investment portfolio, making the stock its 12th largest holding.

Several other large investors also recently modified their holdings of JNJ. Morton Brown Family Wealth LLC raised its holdings in Johnson & Johnson by 78.0% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares in the last quarter. Goodman Advisory Group LLC bought a new position in Johnson & Johnson in the second quarter worth about $39,000. Cardinal Capital Management Inc. lifted its holdings in Johnson & Johnson by 333.3% in the second quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after buying an additional 200 shares during the period. First Bank & Trust boosted its position in Johnson & Johnson by 69.6% during the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after acquiring an additional 156 shares in the last quarter. Finally, Heritage Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $84,000. 67.94% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Barclays began coverage on Johnson & Johnson in a research report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target on the stock. StockNews.com assumed coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Citigroup increased their price target on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a research note on Thursday, November 17th. They set a “neutral” rating and a $170.00 price objective on the stock. Finally, Sanford C. Bernstein decreased their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Seven research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $182.42.

Insider Activity

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at approximately $6,431,835.20. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider William Hait sold 15,000 shares of the firm’s stock in a transaction on Monday, October 24th. The stock was sold at an average price of $171.55, for a total value of $2,573,250.00. Following the transaction, the insider now directly owns 80,236 shares of the company’s stock, valued at approximately $13,764,485.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold 300,750 shares of company stock valued at $52,311,677 in the last ninety days. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Down 0.3 %

Shares of NYSE:JNJ opened at $173.43 on Tuesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a market cap of $453.43 billion, a P/E ratio of 24.15, a PEG ratio of 3.28 and a beta of 0.56. The stock’s fifty day moving average price is $176.33 and its 200-day moving average price is $171.44.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.49 by $0.06. The business had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.60 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. The ex-dividend date is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.61%. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.